Christopher Swann - Pacific Edge Chairman of the Board

PEB -- New Zealand Stock  

NZD 0.28  0.005  1.79%

Mr. Christopher John Swann was Independent Chairman of the Board of Pacific Edge Limited since February 1 2007. Mr. Swann is principal of T.D. Scott and Co. a Dunedin based accountancy and consulting firm. Mr. Swann was principal of the firm for 10 years. Mr. Swann is an experienced business advisor in various industries including the manufacturing publishing health and biotechnology sectors. He is currently manager of the New Zealand Seed Fund which has investment in four biotechnology companies including Pacific Edge. He also holds other directorships and is a member of the NZ Institute of Directors.
  Chairman Since 2007      
64 3 479 5800

Management Efficiency

The company has return on total asset (ROA) of (81.49) % which means that it has lost $81.49 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (158.29) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 138K in total debt with debt to equity ratio (D/E) of 1.2 which is about average as compared to similar companies. Pacific Edge Limited has Current Ratio of 4.33 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 6 records


Trevor JanesAbano Healthcare Group Limited
Alan BougenComvita Limited
Peter WilsonArvida Group Limited
Anthony CarterFisher Paykel Healthcare Corpor
Antony CarterFisher Paykel Healthcare Corpor
Neil CraigComvita Limited

Entity Summary

Pacific Edge Limited, a cancer diagnostic company, develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand and internationally. Pacific Edge Limited was founded in 2001 and is headquartered in Dunedin, New Zealand. Pacific Edge operates under Diagnostics Research classification in New Zealand and is traded on New Zealand Stock Exchange.Pacific Edge Limited (PEB) is traded on New Zealand Stock Exchange in New Zealand and employs 2 people.

Pacific Edge Limited Leadership Team

Chris Gallaher, Independent Director
Parry Guilford, Chief Scientific Officer and Member of Scientific Advisory Board
James Suttie, COO
Kate Rankin, CFO
N Kasabov, Head of Knowledge Engineering Discovery Research Institute (KEDRI)
Jimmy Suttie, COO
Christopher Swann, Chairman of the Board
David Darling, CEO and Executive Director
David Band, Independent Director
David Levison, Director
Charles Sitch, Independent Director
Brent Pownall, Commercial Director of Pacific Edge Diagnostics - New Zealand
Jackie Walker, CEO - Pacific Edge Diagnostics USA Ltd (PEDUSA)
Anatole Masfen, Director
Nikola Kasabov, Head of Knowledge Engineering Discovery Research Institute (KEDRI)
Bryan Williams, Independent Director

Stock Performance Indicators

Current Sentiment - PEB

Pacific Edge Limited Investor Sentiment

Most of Macroaxis users are at this time bullish on Pacific Edge Limited. What is your perspective on investing in Pacific Edge Limited? Are you bullish or bearish?
98% Bullish
2% Bearish
Currently Active Assets on Macroaxis
Purchased over 20 shares of
a day ago
Traded for 117.63
Purchased over 400 shares of
a day ago
Traded for 6.39
Purchased over 40 shares of
a day ago
Traded for 65.83
Purchased few shares of
a day ago
Traded for 183.64
Purchased a lot of shares of
a day ago
Traded for 154.4
Additionally take a look at Your Equity Center. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.